Citations

Showing 10 of 108104 citations.

NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
Ciombor, Kristen K. , Salem, Mohamed E. , Nimeiri, Halla , Iqbal, Syma , Polite, Blasé N. , Deming, Dustin A. , Chan, Emily , Wade, James L. , Uronis, Hope E. , Pasia, Manolo , Bland, Gail L., Wolff, Robert A. , Ohinata, Aki, Ohaji, Chimela, Rogers, Jane E. , Sharma, Padmanee , Morris, Van K. , Singh, Preet Paul , Bekaii‐Saab, Tanios , Eng, Cathy , Rogers, Jane E

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3503-3503

10.1200/jco.2016.34.15_suppl.3503 Get It

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.
Galon, Jérôme , Mlecnik, Bernhard , Marliot, Florence, Bifulco, Carlo , Lugli, Alessandro , Rau, Tilman T. , Hartmann, Arndt , Masucci, Giuseppe , Závadová, Eva, Kawakami, Yutaka , Ascierto, Paolo A. , Marincola, Franco, Fox, Bernard A. , Pagès, Franck , Galon, Jerome , Ou, Fang‐Shu , Zlobec, Inti , Ohashi, Pamela S. , Roehrl, Michael H. A. , Torigoe, Toshihiko , Sargent, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3500-3500

10.1200/jco.2016.34.15_suppl.3500 Get It

Regorafenib dose optimization study (ReDOS): A phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC).
Ciombor, Kristen K. , Farhat, Mohamed, Kirshner, Jeffrey J., Knost, James A., Anderson, Daniel M. , Soori, Gamini S. , Wender, Donald B., Desnoyers, Rodwige J., Bekaii‐Saab, Tanios , Ou, Fang‐Shu , Boland, Patrick M. , Sargent, Daniel J. , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS3630-TPS3630

10.1200/jco.2016.34.15_suppl.tps3630 Get It

Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database.
Matthaiou, Christiana , Renfro, Lindsay A. , Papamichael, Demetris , O’Connell, Michael, Guthrie, Katherine A. , Haller, Daniel G. , Kountourakis, P., Yothers, Greg , Saltz, Leonard B. , Cutsem, Eric Van , Schmoll, Hans‐Joachim , Labianca, Roberto , André, Thierry , Alberts, Steven R. , Sargent, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3620-3620

10.1200/jco.2016.34.15_suppl.3620 Get It

Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials.
Allegra, Carmen J. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Goldberg, Richard M. , Meyers, Jeffrey P., Sinicrope, Frank A. , Shi, Qian , Yothers, Greg , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3600-3600

10.1200/jco.2016.34.15_suppl.3600 Get It

Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.
Drabick, Joseph J. , Khleif, Samir N. , Link, Charles J., Vahanian, Nicholas N., Shaheen, Montaser , Rixe, Olivier , Zakharia, Yousef , McWilliams, Robert R. , Munn, David H. , Kennedy, Eugene Paul , Milhem, Mohammed

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3075-3075

10.1200/jco.2016.34.15_suppl.3075 Get It

Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.
Baas, Paul, Molina, Julian R. , Kim, Joo-Hang , Arvis, Catherine Dubos, Ahn, Myung‐Ju , Fidler, Mary J. , Surmont, Veerle, Castro, Gilberto de , Shentu, Yue , Dolled‐Filhart, Marisa, Im, Ellie, Herbst, Roy S. , Baas, Paul, Perez‐Gracia, José Luis , Felip, Enriqueta , Kim, Dong‐Wan , Han, Ji-Youn , Majem, Margarita , Garrido, Marcelo , Garon, Edward B.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3030-3030

10.1200/jco.2016.34.15_suppl.3030 Get It

First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.
Beg, Muhammad Shaalan , Sachdev, Jasgit C. , Lim, Ho Yeong , Kim, Tae‐You, Becerra, Carlos, Bader, Andreas G. , Stoudemire, Jay, Smith, Susan, Kim, Sinil, Hong, David S. , Brenner, Andrew Jacob , Borad, Mitesh J. , Park, Keunchil , Smith, Susan, Kang, Yoon‐Koo

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS2597-TPS2597

10.1200/jco.2016.34.15_suppl.tps2597 Get It

Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
Frankel, Paul , Herzog, Josef , Cynthia, X. , Cigler, Tessa, Cream, Leah, Harvey, Harold A., Nanda, Rita , Chew, Helen K. , Tongeren, Lily R. Van, Ferry‐Galow, Katherine V., Somlo, George, Weitzel, Jeffrey N. , Arun, Banu , Beumer, Jan Hendrik , Sparano, Joseph A. , Vahdat, Linda T. , Goetz, Matthew P. , Gandara, David R. , Piekarz, Richard , Synold, Timothy Walter

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2549-2549

10.1200/jco.2016.34.15_suppl.2549 Get It

A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).
Demeure, Michael J. , Armaghany, Tannaz , Ejadi, Samuel, Ramanathan, Ramesh K., Elfiky, Aymen, Smith, David C. , Sekar, Shobana , Carpten, John D. , Fredlund, Paul, Niforos, Demi, Dye, Andrew, Gahir, Sarabjit, Semple, Sean C., Kowalski, Mark , Strosberg, Jonathan , Whitsett, Timothy G. , Liang, Winnie S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2547-2547

10.1200/jco.2016.34.15_suppl.2547 Get It